Table 2.
Scenario | Costs | Increase in Cost |
MVFD | Gain in MVFD |
MV-Free Survival |
Gain in MV-Free Survival |
Incremental Cost-Effectiveness of Regimen |
|
---|---|---|---|---|---|---|---|---|
$ | $ | $/MVFD Gained | $/MVFD Alive Gained |
|||||
Base-case analysis | ||||||||
Probabilistic analysis (crossover to lorazepam)* | ||||||||
Lorazepam | 52,009 | 12.183 | 11.563 | Propofol dominates lorazepam in 91% of simulations |
||||
Propofol | 45,631 | (6,378) | 15.917 | (3.734) | 14.956 | (3.393) | ||
Secondary analyses | ||||||||
Probabilistic analysis (crossover to midazolam)† | ||||||||
Lorazepam | 52,954 | 12.803 | 12.297 | Propofol dominates lorazepam in 92% of simulations |
||||
Propofol | 44,740 | (8,214) | 16.172 | (3.369) | 15.338 | (3.041) | ||
Probabilistic analysis including midazolam | ||||||||
Lorazepam | 55,038 | 12.126 | 11.46 | |||||
Propofol | 44,969 | (10,069) | 15.156 | (3.03) | 14.324 | (2.864) | Propofol dominates lorazepam in 92% of simulations |
|
Midazolam | 43,908 | (1,061) | 15.402 | 0.246 | 14.428 | 0.104 | Midazolam dominates lorazepam in 94% of simulations |
MVFD = mechanical ventilator-free days (days without mechanical ventilation within the 28 days following intubation), MV = mechanical ventilation. Parentheses denote negative value.
Assumes crossover to lorazepam for propofol intolerance and vice versa.
Assumes crossover to midazolam for propofol intolerance and to propofol for lorazepam intolerance.